(3 minutes read)
- Africa will get 110 doses of Moderna covid 19 vaccine, which is billed to be a pathbreaking achievement for the least vaccinated continent, where the pandemic did not spread like much unlike other regions
- Moderna will be delivering the first 15 million doses by the end of this year
- Over 35 million doses will be supplied in the first quarter of 2022 and up to 60 million in the second quarter. This could be a cheerful news for the region since it has been complaining against the vaccine nationalism being followed by the rich countries
- It is still to be ascertained as to which countries will be getting the vaccines
Africa will get 110 doses of Moderna covid 19 vaccine, which is billed to be a pathbreaking achievement for the least vaccinated continent, where the pandemic did not spread like much unlike other regions.
Moderna will be delivering the first 15 million doses by the end of this year. Over 35 million doses will be supplied in the first quarter of 2022 and up to 60 million in the second quarter. This could be a cheerful news for the region since it has been complaining against the vaccine nationalism being followed by the rich countries. It is still to be ascertained as to which countries will be getting the vaccines.
African countries will first purchase 50 million Moderna vaccines with the option for 20 million a month in April, May, and June, depending on the company’s performance in December. If this deal goes through, African nations will be able to reach its target of vaccinating 450 million people by September 2022. That’s half of the target of vaccinating 70 percent of the continent’s population, or 900 million people.
African nations earlier entered into an agreement with Johnson & Johnson for buying up to 400 million doses. The vaccination rate in Africa is a little over 5%. This agreement is separate from its deal with the global COVAX project to supply up to 500 million doses from late this year through 2022. COVAX aims to supply doses to low- and middle-income countries.
